Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631953 | 0.92 | SIGMAR1 (0.44) | SIGMAR1KCNH2OPRM1HTR2AICMT | |
| SCHEMBL19631999 | 0.87 | OPRM1 (0.44) | SIGMAR1KCNH2OPRM1HTR2ADRD2 | |
| SCHEMBL19631581 | 0.85 | OPRM1 (0.35) | SIGMAR1KCNH2OPRM1 | |
| SCHEMBL19631680 | 0.85 | SIGMAR1 (0.46) | SIGMAR1KCNH2OPRM1HTR2AGRM2 | |
| SCHEMBL19631708 | 0.84 | SIGMAR1 (0.45) | SIGMAR1KCNH2OPRM1DRD2 | |
| SCHEMBL19631716 | 0.84 | SIGMAR1 (0.45) | SIGMAR1KCNH2OPRM1DRD2 | |
| SCHEMBL19631654 | 0.84 | SIGMAR1 (0.45) | SIGMAR1KCNH2OPRM1DRD2 | |
| SCHEMBL19631886 | 0.82 | KCNH2 (0.40) | SIGMAR1KCNH2OPRM1HTR2AGRM2 | |
| SCHEMBL19631759 | 0.81 | SLC6A3 (0.49) | SIGMAR1KCNH2OPRM1HTR2AGRM2 | |
| SCHEMBL19631724 | 0.80 | OPRM1 (0.44) | SIGMAR1KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | claimed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | claimed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | claimed |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| WO-2017198339-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | SIGMAR1 2/4885KCNH2 1972/4885OPRM1 4/4885 |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | SIGMAR1 2/4885KCNH2 1972/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.